Literature DB >> 10380885

p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis.

I de Belle1, R P Huang, Y Fan, C Liu, D Mercola, E D Adamson.   

Abstract

The human fibrosarcoma cell line, HT1080, clone H4, was used to determine if the transformation suppressive functions of p53 and Egr-1 have the same underlying mechanism. This cell line expresses only mutant p53 and no detectable Egr-1. H4 clones stably expressing Egr-1 are less transformed in proportion to the level of Egr-1 expressed, acting through the induction of the TGFbeta1 gene. Here, H4 cells and the highest Egr-1 expressing clone were transfected with a vector expressing normal human p53 to derive stable clones expressing p53. The expression of p53 in H4 cells inhibited transformed growth and reduced tumorigenicity. The effect of coexpression of both p53 and Egr-1 was additive, producing cell lines with 30% of normal growth rate and sevenfold reduced tumorigenicity compared with control lines. These results indicated that each factor may act independently by different pathways, although each additively increased the level of p21WAF1 cell cycle inhibitor. However, exposure of the H4-derived cells to UV-C irradiation produced contrasting effects. Cell cycle analyses showed that the presence of p53 was associated with loss of the G1 and S cells to apoptosis after irradiation. In contrast, the expression of Egr-1 increased entry into S/G2 phase of the cell cycle with little apoptosis via a mechanism involving elevated FAK and low caspase activities. Apoptosis was observed only in the cell lines that expressed no Egr-1, especially those expressing wt-p53, and was preceded by high caspase activity. In summary, Egr-1 suppressed transformation and counteracted apoptosis by the coordinated activation of TGFbeta1, FN, p21 and FAK, leading to enhanced cell attachment and reduced caspase activity. In the doubly expressing cell line, the survival effect of Egr-1 was dominant over the apoptotic effect of p53.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380885     DOI: 10.1038/sj.onc.1202696

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Authors:  Taeyoung Koo; Il-Kyu Choi; Minjung Kim; Jung-Sun Lee; Eonju Oh; Jungho Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2012-02-21       Impact factor: 5.695

2.  Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Authors:  Dejan Juric; Sanja Sale; Robert A Hromas; Ron Yu; Yan Wang; George E Duran; Robert Tibshirani; Lawrence H Einhorn; Branimir I Sikic
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-23       Impact factor: 11.205

3.  Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms.

Authors:  John M Routes; Kristin Morris; Misoo C Ellison; Sharon Ryan
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.

Authors:  Kathryn T Bieging; Kamonwan Fish; Subbarao Bondada; Richard Longnecker
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

Review 5.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

6.  Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses.

Authors:  Peter S T Yuen; Sang-Kyung Jo; Mikaela K Holly; Xuzhen Hu; Robert A Star
Journal:  Physiol Genomics       Date:  2006-02-28       Impact factor: 3.107

7.  Expression of early growth response gene-1 in precancerous lesions of gastric cancer.

Authors:  Seon-Young Park; Ji-Young Kim; Su-Mi Lee; Jin Ook Chung; Kyung-Hwa Lee; Chung-Hwan Jun; Chang-Hwan Park; Hyun-Soo Kim; Sung-Kyu Choi; Jong-Sun Rew; Young-Do Jung; Yong Han Lee
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

8.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

9.  Egr-1 promotes cell proliferation and invasion by increasing β-catenin expression in gastric cancer.

Authors:  Ting Sun; Hua Tian; Yu-Guang Feng; Ya-Qin Zhu; Wei-Qian Zhang
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

10.  Identification of G1-regulated genes in normally cycling human cells.

Authors:  Maroun J Beyrouthy; Karen E Alexander; Amy Baldwin; Michael L Whitfield; Hank W Bass; Dan McGee; Myra M Hurt
Journal:  PLoS One       Date:  2008-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.